Concerning immune therapies, the most pronounced clinical benefits have been observed with immune checkpoint blockers (anti-PD1/PDL1, anti-CTLA4 mAb), despite multiple cellular players comprising the TME and aiding in tumor progression and therapy resistance. This evidence concerns the gene CTLA4 and neoplasm.